New Vaccine Technologies

Note: Supplemental materials are not guaranteed with Rental or Used book purchases.

ISBN: 9781587060502 | 1587060507
Cover: Hardcover
Copyright: 6/1/2001

Rent

(Recommended)

$126.54

Term

Due

Price

Semester

Dec 13

$140.60

Quarter

Aug 20

$133.57

Short Term

Jul 26

$126.54

*This item is part of an exclusive publisher rental program and requires an additional convenience fee. This fee will be reflected in the shopping cart.
Buy New

Usually Ships in 3-5 Business Days

$192.09
eBook

Available Instantly

Online: 180 Days

Downloadable: 180 Days

$142.31

(Eurekah.com) BioChem Pharma/Shire Biologics, Northborough, MA. Focuses on the application and development of new technologies for creating new vaccines. The general categories discussed are: design of the overall vaccine, discovery of new lead and candidate antigens, production and mode of administration for human use. DNLM: Vaccines.

Preface

New Technologies for Making Vaccines

(20)

Ronald W. Ellis

Introduction

(3)

Live Vaccines

(4)

Subunit/Inactivated Vaccines

(6)

DNA (Nucleic Acid) Vaccines

(1)

Formulation of Antigens

(1)

Conclusion

(5)

Clinical Issues for New Technologies

(12)

Luc Hessel

Introduction

(1)

Definition of the Medical Needs

(1)

Moving from Preclincal to Clinical Development

(1)

Demonstration of the Proof-of-Principle

(1)

Design and Implementation of a Clinical Development Plan

(4)

Continuous Assessment of Safety and Efficacy

(1)

Specific Issues

(2)

Conclusion

(3)

Regulatory Issues

(11)

Marion F. Gruber

Paul G. Richman

Julianne C. M. Clifford

Introduction

(1)

Federal Regulations Pertaining to Vaccines

(2)

Premarketing Phase

(6)

Postmarketing Phase

(3)

In-Licensing Issues and Vaccine Technologies

(7)

Dale R. Spriggs

Introduction

(1)

Why Do Companies In-License?

(2)

How Do Companies Evaluate Licensing Opportunities?

(2)

How Can an Inventor Make the Technology More Attractive?

(1)

Framework of a Licensing Agreement

(1)

What Does the Future Hold?

(1)

CODA

(1)

Live Vaccines

(39)

Alan R. Shaw

Smallpox Vaccine

(1)

Japanese Encephalitis Vaccines

(1)

Yellow Fever Vaccines

(1)

Poliovirus Vaccines

(3)

Measles Vaccines

(2)

Rubella Vaccines

(2)

Mumps Vaccines

(3)

Trivalent Measles-Mumps-Rubella Vaccines

(3)

Quadrivalent Measles-Mumps-Rubella-Varicella Vaccines

(1)

Varicella Vaccines

(3)

Rotavirus Vaccines

(3)

Live Attenuated Influenza Vaccines

(17)

Recombinant Live Attenuated Viral Vaccines

(11)

Richard R. Spaete

Advantages and Concerns Associated with the Use of Live Attenuated Vaccines

(1)

Vaccine Efforts for Herpesviruses

(6)

Prospects for the Future

(4)

Live Viral Vectors

101

(33)

Elizabeth B. Kauffman

Michel Bublot

Russell R. Getting

Keith J. Limbach

Steven E Pincus

Jill Taylor

DNA Viruses

102

(12)

RNA Viruses

114

(20)

Inactivated Virus Vaccines

134

(18)

Andrew D. Murdin

Benjamin Rovinski

Suryaprakash Sambhara

Introduction

134

(1)

Current Inactivated Virus Vaccines

134

(3)

Issues Affecting the Use of Inactivated Virus Vaccines

137

(9)

Conclusion

146

(6)

Live Attenuated Bacterial Vaccines

152

(20)

Kevin P. Killeen

Victor J DiRita

Introduction

152

(1)

Types of Vaccines

152

(3)

Live Attenuated Bacterial Vaccines

155

(1)

Live Attenuated Mycobacterium Bovis (BCG Tuberculosis Vaccine)

155

(3)

Immune Correlates of Protection

158

(1)

Live Attenuated Salmonella typhi (Typhoid Fever Vaccines and Vaccine Candidates)

158

(3)

Live Attenuated Shigella Sp (Shigellosis Vaccine Candidates)

161

(3)

Live Virulence-Attenuated Vibrio cholerae (Cholera Vaccines)

164

(1)

Animal Model

165

(1)

Vaccine Efforts

165

(7)

Live Attenuated Bacterial Vectors

172

(14)

Sims K. Kochi

Kevin P. Killeen

Introduction

171

(1)

Salmonella Vectors

172

(3)

bacille Calmette-Guerin

175

(1)

Vibrio Vectors

176

(2)

Listerial Vectors

178

(1)

Next Generation Bacterial Vectors

179

(1)

DNA Delivery

180

(2)

Summary

182

(4)

Protein-Based Vaccines

186

(28)

Sheena M. Loosmore

Gavin R. Zealey

Raafat E.F. Fahim

Introduction

186

(1)

Pediatric Vaccines

186

(3)

Adult Vaccines

189

(5)

Vaccines Against Nosocomial Infections

194

(1)

Cancer Vaccines

194

(3)

Vaccines Against Autoimmune Diseases

197

(1)

Current Technologies

198

(1)

Emerging Technologies

199

(2)

Summary

201

(13)

Peptide Vaccines

214

(13)

Damu Yang

Gregory E. Holt

Michael P. Rudolf

Markwin P. Velders

Remco M. P. Brandt

Eugene D. Kwon

W. Martin Kast

Introduction

214

(1)

Molecular Basis for the Development of Peptide Vaccines

214

(1)

Advantages and Disadvantages of Peptide-Based Vaccines

215

(1)

Adjuvants and Delivery Systems

215

(1)

Design of Peptide Vaccines: Synthetic Peptides as B-Cell Vaccines

216

(1)

Peptide-Based T-Cell Vaccines. Identification of Peptide Epitopes Recognized by T Cells

217

(1)

Synthetic Peptides as T-Cell Vaccines

217

(1)

Recombinant Vaccines Expressing T-Cell Epitopes

218

(1)

Adoptive Cellular Therapy

219

(1)

Summary and Perspectives

220

(7)

Polysaccharide Vaccines

227

(13)

Stephen Freese

Polysaccharide Immunity

227

(1)

Issues in Designing a Conjugate

227

(2)

Issues in Making a Conjugate

229

(3)

Applications

232

(8)

DNA Vaccines

240

(23)

Daniel E. McCallus

Catherine J. Pachuk

Shaw-guang Lee

C. Satishchandran

Introduction

240

(1)

Gene Expression

241

(1)

Mechanisms of Immunostimulation

242

(3)

Routes of Administration

245

(3)

Intracellular Delivery of DNA Vaccines

248

(3)

Safety of Nucleic Acid Vaccines

251

(2)

Future Directions of DNA Vaccines

253

(3)

Summary

256

(7)

Plant-Derived Vaccines

263

(11)

Amanda M. Walmsely

Charles J. Arntzen

Introduction

263

(1)

Mucosal Vaccines

263

(1)

Production of Plant-Derived Vaccines

264

(1)

Plant-Derived Vaccines

265

(5)

Summary

270

(1)

Future Use of Plant-Delivered Vaccines

270

(4)

Biological Aspects and Prospects for Adjuvants and Delivery Systems

274

(18)

Bror Morein

Ke-Fei Hu

Introduction

274

(3)

Innate Immunity: The Gateway to an Acquired Immune Response

277

(3)

APCs Instruct the Acquired Immune System

280

(1)

Immune Modulation is Based on Cross-Talk Between Innate Immunity and Helper T Cells

281

(1)

The Collaboration Between the Complement System and B Cells: Roles for Adjuvants

282

(1)

Immune Modulation For CTL

283

(1)

Delivery Systems

284

(1)

Vaccines for Newborns and Elderly Require Suitable Strong Adjuvants

285

(1)

The Present Situation and Future Aspects of Adjuvants and Delivery Systems

286

(6)

Transcutaneous Immunization

292

(13)

Gregory M. Glenn

Introduction

292

(1)

Barriers and Targets for TCI

292

(2)

Adjuvants and TCI

294

(1)

Immune Responses to Transcutaneous Immunization

295

(1)

Mucosal Responses

296

(2)

Diversity of Antigens

298

(1)

Delivery Options Using Transcutaneous Immunization

299

(1)

Optimization for Enhancement of the Immune Response

299

(3)

Human Studies

302

(1)

Conclusions

302

(3)

Index

305

Please wait while the item is added to your bag...

FREE SHIPPING

Amazon no longer offers textbook rentals. We do!

New Vaccine Technologies

Summary

Table of Contents

Supplemental Materials